Laboratory of Analytical Chemistry and Biopolymer Structure Analysis, Department of Chemistry, University of Konstanz, 78457 Konstanz, Germany.
Eur J Med Chem. 2012 Jun;52:173-83. doi: 10.1016/j.ejmech.2012.03.016. Epub 2012 Mar 16.
Here we report on the design, synthesis and biochemical characterization of multifunctional bioconjugates containing two chemotherapeutic agents, daunorubicin and methotrexate, coupled to the GnRH-III decapeptide, which served as a targeting moiety. This represents a possible approach to increase the receptor mediated tumor targeting and consequently the cytostatic effect of anticancer drug-peptide bioconjugates. The multifunctional bioconjugates were prepared according to two drug design approaches recently developed by our group. Both bifunctional GnRH-III derivatives, [(4)Lys]-GnRH-III (Glp-His-Trp-Lys-His-Asp-Trp-Lys-Pro-Gly-NH(2)) and [(8)Lys(Lys)]-GnRH-III (Glp-His-Trp-Ser-His-Asp-Trp-Lys(Lys)-Pro-Gly-NH(2)), contain two free amino groups suitable for the attachment of two anticancer drugs, such as methotrexate and daunorubicin. The drugs were chosen with respect to their different mechanisms of action, with the goal of increasing the antitumor effect of the bioconjugates. The in vitro cytostatic effect of the bioconjugates was determined on MCF-7 human breast, HT-29 human colon and LNCaP human prostate cancer cells by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Their in vitro stability/degradation in human serum and in the presence of rat liver lysosomal homogenate was investigated by liquid chromatography in combination with mass spectrometry. The influence of the multifunctional bioconjugates on the cell adhesion and cell proliferation was studied on Mono Mac 6 human leukemic monocytes. It was found that (1) all synthesized bioconjugates had in vitro cytostatic effect; (2) they were stable in human serum for at least 24 h; (3) they were hydrolyzed in the presence of lysosomal homogenate and (4) they exerted a moderate cell-cell adhesion inducing effect. These results demonstrate that multifunctional bioconjugates containing two different anticancer drugs attached to the same GnRH-III targeting moiety could be successfully prepared and resulted in higher in vitro cytostatic effect than the monofunctional bioconjugates containing either methotrexate or daunorubicin, in particular on HT-29 human colon cancer cells.
在这里,我们报告了含有两种化疗药物(柔红霉素和氨甲蝶呤)与 GnRH-III 十肽偶联的多功能生物缀合物的设计、合成和生化特性研究,该十肽用作靶向部分。这代表了一种增加受体介导的肿瘤靶向并因此增加抗癌药物-肽生物缀合物细胞抑制作用的可能方法。这些多功能生物缀合物是根据我们小组最近开发的两种药物设计方法制备的。两种双功能 GnRH-III 衍生物,[(4)Lys]-GnRH-III(Glp-His-Trp-Lys-His-Asp-Trp-Lys-Pro-Gly-NH(2))和[(8)Lys(Lys)]-GnRH-III(Glp-His-Trp-Ser-His-Asp-Trp-Lys(Lys)-Pro-Gly-NH(2)),都含有两个游离氨基,适合连接两种抗癌药物,如氨甲蝶呤和柔红霉素。选择这些药物是基于它们不同的作用机制,目的是增加生物缀合物的抗肿瘤效果。通过 3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴化物测定法,在 MCF-7 人乳腺癌、HT-29 人结肠癌细胞和 LNCaP 人前列腺癌细胞上测定了生物缀合物的体外细胞抑制作用。通过液相色谱与质谱联用研究了它们在人血清中和大鼠肝溶酶体匀浆中的体外稳定性/降解。研究了多功能生物缀合物对 Mono Mac 6 人白血病单核细胞的细胞黏附和细胞增殖的影响。结果表明:(1) 所有合成的生物缀合物均具有体外细胞抑制作用;(2) 它们在人血清中至少稳定 24 小时;(3) 在溶酶体匀浆存在下被水解;(4) 它们具有适度的细胞间黏附诱导作用。这些结果表明,含有两种不同抗癌药物的多功能生物缀合物与相同 GnRH-III 靶向部分偶联,可以成功制备,并导致更高的体外细胞抑制作用,特别是对 HT-29 人结肠癌细胞,比含有氨甲蝶呤或柔红霉素的单功能生物缀合物更高。